Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Study Overview The PROGRESS-GT LOPD trial is an early-stage clinical study ...

U.S. nonprofit AARP projected on Thursday that out-of-pocket savings from the first 10 Medicare Part D drugs negotiated under ...

George Tidmarsh and Vinay Prasad have taken leadership roles at CDER and CBER, respectively, impacting FDA's drug and ...

The global drug-device combination products market is projected to experience a compound annual growth rate (CAGR) of ...

Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome, a rare, genetic disease that leads to chronic ...

The first ‘kleiner’ Rhein Derby of the season between Bayer Leverkusen and 1.FC Köln saw Köln looking to stop their slide ...

Bayer stock may offer upside despite litigation and debt risks. Learn how recent developments could unlock value for BAYZF ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Product designation ...

Shares of Bayer are surging on their home exchange in Germany after the U.S. Solicitor General supported its efforts to have the Supreme Court review rulings on whether Roundup weed killer, produced ...

Shares in Bayer rose after the company reported positive results from a clinical trial for an experimental stroke-preventing drug which had previously showed to be ineffective in another trial. The ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

Bayer and Merck & Co, Inc. said heart-failure drug candidate vericiguat didn't meet the primary target of a late-stage study. The German conglomerate on Monday said vericiguat in the phase 3 Victor ...